Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)

Trial Profile

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Registrational
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top